Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

The USAN designation reflects Okyo Pharma’s commitment to developing new therapies for unmet medical needs in ophthalmology. The suffix “-mod” in urcosimod denotes its classification as a modulator of ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Mortality rates among patients with GCA in Spain are similar to that of the general population, with older age and male sex linked to higher mortality.

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Northwestern Medicine investigators have developed a new avenue to reprogram compromised immune cells to act against tumors, ...

A study found that injecting mesenchymal stem cells into periocular tissue effectively reduces eye inflammation without ...

The distinct population of endothelial cells that line blood vessels in the insulin-producing "islets" of the human pancreas ...

Scientists uncover an enzyme that boosts cancer cell metabolism to fuel growth. The enzyme, GUK1, supports metabolism in cancer cells to help tumors grow.

A new study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease and ...